Cumberland Pharmaceuticals Income Statement
View: Annual
| Dec 06 | Dec 05 | Dec 04 | |
|---|---|---|---|
| Revenue | 17.8 | 10.7 | 12.0 |
| Cost of Goods Sold | 2.4 | 0.5 | 0.8 |
| Gross Profit | 15.4 | 10.2 | 11.2 |
| Gross Profit Margin | 86.5% | 95.0% | 93.2% |
| SG&A Expense | 13.2 | 9.4 | 9.9 |
| Depreciation & Amortization | -- | -- | -- |
| Operating Income | 2.2 | 0.8 | 1.6 |
| Operating Margin | 12.5% | 7.0% | 13.0% |
| Nonoperating Income | 0.2 | 0.1 | 0.0 |
| Nonoperating Expenses | 0.7 | 0.1 | 1.0 |
| Income Before Taxes | 1.7 | 0.8 | 0.6 |
| Income Taxes | (2.7) | (1.2) | 0.0 |
| Net Income After Taxes | 4.4 | 2.0 | 0.6 |
| Continuing Operations | 4.4 | 2.0 | 0.6 |
| Discontinued Operations | 0.0 | 0.0 | 0.0 |
| Total Operations | 4.4 | 2.0 | 0.6 |
| Total Net Income | 4.4 | 2.0 | 0.6 |
| Net Profit Margin | 24.7% | 18.3% | 4.6% |
| Diluted EPS from Total Net Income ($) | -- | -- | -- |
| Dividends per Share | -- | -- | -- |
